Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allarity Therapeutics, Inc.ALLR · Entity 7594 | Director | January 28, 2026 | May 11, 2026 |
| Radius Health, Inc.RDUS · Entity 124173 | Director · President and CEO | February 20, 2020 | February 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allarity Therapeutics, Inc.
Report date January 28, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 25,000 · Balance 25,000 F1: The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.
Radius Health, Inc.
Report date February 20, 2020 · Filed February 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.96 · Expires 2030-02-20 | Direct | 107,000 |
Reported balance
After 2020-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-20 · Grant · Acquired 107,000 · Balance 107,000 F1: 25% of the shares subject to the stock option shall vest on February 20, 2021, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option shall vest on February 20, 2021, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONCERT PHARMACEUTICALS, INC.
Report date March 06, 2023 · Filed March 06, 2023
Section 16 reporting ended · disclosed 2023-03-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-03-06 · Other · Disposed 5,125 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2) F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-03-06 · Disposition to issuer · Disposed 16,400 · Balance 0 F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.02 · Expires 2029-06-12 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-06 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.16 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-06 · Disposition to issuer · Disposed 10,250 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)
F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.
F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5)
F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed May 11, 2026 19:21 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-054430 · ownership.xml · nonDerivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:37 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,250 | Not disclosed Strike: $4.26 | Not disclosed |
DisclosureSEC source: 0001209191-23-016164 · doc4.xml · derivative · entry 5 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,250 shares Expires 2031-06-09 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:37 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $9.16 | Not disclosed |
DisclosureSEC source: 0001209191-23-016164 · doc4.xml · derivative · entry 4 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:37 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $11.02 | Not disclosed |
DisclosureSEC source: 0001209191-23-016164 · doc4.xml · derivative · entry 3 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-06-12 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:37 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerCommon Stock | 16,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016164 · doc4.xml · nonDerivative · entry 2 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest. F3 · price: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:37 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | OtherCommon Stock | 5,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016164 · doc4.xml · nonDerivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2) F2 · price: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:14 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 16,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-036286 · doc4.xml · nonDerivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,525 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 9, 2023 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant. F2 · price: Not applicable. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 08:40 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantStock Option (right to buy) · Derivative | 10,250 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-21-039744 · doc4.xml · derivative · entry 2 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,250 Underlying: Common Stock · 10,250 shares Expires 2031-06-09 F3 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022). Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 08:40 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 5,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-039744 · doc4.xml · nonDerivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,125 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 10, 2022 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant. F2 · price: Not applicable. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 17:03 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.16 | $0.00 |
DisclosureSEC source: 0001209191-20-036346 · doc4.xml · derivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 11, 2021, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 11, 2021). Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 17:56 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 107,000 | $0.00 Strike: $19.96 | $0.00 |
DisclosureSEC source: 0001209191-20-012148 · doc4.xml · derivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 20, 2021, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:01 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-19-037560 · doc4.xml · derivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a three-year period measured from the date of grant, subject to the Reporting Person's continued service as a director, and will become exercisable in full upon a change in control of the Issuer. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:15 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantPerformance Stock Units · Derivative | 71,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013710 · doc4.xml · derivative · entry 2 Hoeiland Jesper · CIK 0001711694 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2029-02-22 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. 50% of the restricted stock units shall vest upon the execution of a Board approved partnership for elacestrant within twelve months from the grant date of February 22, 2019, and, assuming such performance condition is achieved, the remaining restricted stock units shall vest on the third anniversary of the grant date of February 22, 2019, subject to continued service with RDUS through such dates. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. 50% of the restricted stock units shall vest upon the execution of a Board approved partnership for elacestrant within twelve months from the grant date of February 22, 2019, and, assuming such performance condition is achieved, the remaining restricted stock units shall vest on the third anniversary of the grant date of February 22, 2019, subject to continued service with RDUS through such dates. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:15 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 128,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001209191-19-013710 · doc4.xml · derivative · entry 1 Hoeiland Jesper · CIK 0001711694 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 128,000 shares Expires 2029-02-22 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 19:43 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $37.83 | $0.00 |
DisclosureSEC source: 0001209191-18-010552 · doc4.xml · derivative · entry 1 Hoiland Jesper · CIK 0001711694 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2028-02-12 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 17:14 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 6,800 | $29.04 | $197,450.24 |
DisclosureSEC source: 0001209191-17-059635 · doc4.xml · nonDerivative · entry 1 Hoiland Jesper · CIK 0001711694 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.0516 to $29.00, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares of Common Stock purchased at each separate price. Read SEC document |
| September 15, 2017 Filed Sep 15, 2017 13:13 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 6,100 | $32.72 | $199,608.47 |
DisclosureSEC source: 0001209191-17-052911 · doc4.xml · nonDerivative · entry 1 Hoiland Jesper · CIK 0001711694 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.688 to $32.7387, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Common Stock purchased at each separate price. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 16:52 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 305,000 | $0.00 Strike: $42.97 | $0.00 |
DisclosureSEC source: 0001209191-17-045520 · doc4.xml · derivative · entry 1 Hoiland Jesper · CIK 0001711694 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 305,000 shares Expires 2027-07-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on July 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.